It typically takes a while for the Street to really buy into a better-than-expected story, and it looks like catch-up is still the name of the game around French drug giant Sanofi (SNY). While growth is not great in absolute terms, there's more value here than many analysts seem able to see. Investors can take advantage of a company that should offer above-average growth and yield over the next three to five years.
Please click here for more:
Sanofi Still Surprising And Surpassing